

after transfection, the cells were conditioned 48 h in OptiMEM containing 5% newborn calf serum. After withdrawal of the media for ELISA measurements, the APP expression in the cells were investigated by western blot using monoclonal antibody 22C11 (Roche Diagnostics). Media was conditioned and analyzed for A β levels by the same A β 42- and A β 40-specific sandwich ELISA systems as used for human plasma (Citron, et al. (1997)). The A β 42 and A β 40 concentrations and A β 42/40 ratios are shown in Table 1.--

IN THE CLAIMS:

Cancel claims 17-23 without prejudice.

Add the following new claims:

--24. (new) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of a non-wildtype protofibril.

--25. (new) The method according to claim 24, wherein said protofibril comprises a mutated form of A β peptide.

--26. (new) The method according to claim 24, wherein said protofibril comprises the peptide A β -Arc (SEQ ID NO:1) or an active fragment thereof.

--27. (new) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administration to said subject a therapeutically effective antibody or an active fragment thereof, against a non-wildtype protofibril.

--28. (new) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administration to said subject a therapeutically effective antibody or an active fragment thereof, produced by immunization with a non-wildtype protofibril.


--29. (new) The method according to claim 27, wherein said antibody or fragment thereof, reacts against a protofibril comprising the amino acid sequence KLVFFAEDV (SEQ ID NO:2).

--30. (new) The method according to claim 27, wherein said antibody or fragment thereof, reacts against a protofibril comprising a mutated form of A β peptide.

--31. (new) The method according to claim 27, further comprising administering an antibody or a fragment thereof, which reacts against a protofibril comprising the peptide A β -Arc (SEQ ID NO:1) or an active fragment thereof.

--32. (new) The method according to claim 27, wherein said antibody or fragment thereof is monoclonal.

--33. (new) The method according to claim 27, wherein said antibody or fragment thereof is human or humanized.

--34. (new) The method according to claim 28, wherein said antibody or fragment thereof, reacts against a protofibril comprising the amino acid sequence KLVFFAEDV (SEQ ID NO:2).

CS
--35. (new) The method according to claim 28, wherein said antibody or fragment thereof, reacts against a protofibril comprising a mutated form of A β peptide.

--36. (new) The method according to claim 28, further comprising administering an antibody or a fragment thereof, which reacts against a protofibril comprising the peptide A β -Arc (SEQ ID NO:1) or an active fragment thereof.

--37. (new) The method according to claim 28, wherein said antibody or fragment thereof is monoclonal.

--38. (new) The method according to claim 28, wherein said antibody or fragment thereof is human or humanized.--